贝伐珠单抗生物类似药 bevacizumab-awwb 在转移性结直肠癌美国患者中的真实世界应用。
Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer.
机构信息
ConcertAI, 6555 Quince Road, Suite 400, Memphis, TN 38119, USA.
Center for Observational Research, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA.
出版信息
Future Oncol. 2021 Dec;17(36):5119-5127. doi: 10.2217/fon-2021-0588. Epub 2021 Oct 26.
Evaluated real world use of bevacizumab-awwb (MVASI), a bevacizumab biosimilar, for treating metastatic colorectal cancer (mCRC). Adult mCRC patients who received bevacizumab-awwb during the first year after market availability were identified from the ConcertAI oncology dataset. Of 304 patients, 47% initiated bevacizumab-awwb as reference product (RP) naive patients and 53% received bevacizumab-awwb with prior exposure to RP. Overall, 78% received bevacizumab-awwb as first-line therapy; the proportion was higher (91%) in RP-naive patients. Among RP-experienced patients, 83% were transitioned from RP to bevacizumab-awwb in the same line without disease progression; of those, the majority (83%) were transitioned within 28 days. Early evidence from US oncology practices suggests clinical adoption of bevacizumab-awwb in treating mCRC patients.
评估贝伐珠单抗生物类似药 bevacizumab-awwb（MVASI）在转移性结直肠癌（mCRC）治疗中的真实世界应用。从 ConcertAI 肿瘤学数据集确定了市场准入后第一年接受 bevacizumab-awwb 治疗的成年 mCRC 患者。在 304 名患者中，47%的患者为首次接受 bevacizumab-awwb 治疗的参考产品（RP）初治患者，53%的患者在接受 bevacizumab-awwb 治疗前曾接受过 RP 治疗。总体而言，78%的患者接受 bevacizumab-awwb 作为一线治疗；在 RP 初治患者中，这一比例更高（91%）。在 RP 治疗经验丰富的患者中，83%的患者在疾病未进展的情况下从 RP 转换为 bevacizumab-awwb 同线治疗；其中，大多数（83%）在 28 天内完成转换。来自美国肿瘤学实践的早期证据表明，bevacizumab-awwb 在治疗 mCRC 患者中的临床应用得到了采纳。
Zotero 插件